https://pharmoniq.com/news/boehringer-sino-biopharm-six-cancer-programs-358m-7b-deal PharmoniQ en 2026-11-08T14:02:37.680Z Boehringer Pledges $358M, Up to $7B More, for 6 Sino Cancer Programs Boehringer Ingelheim, Sino Biopharmaceutical, licensing, antibody-drug conjugates, China biotech https://pharmoniq.com/news/agios-cuts-over-100-rd-roles-fda-delays-sickle-cell-ruling PharmoniQ en 2026-11-08T08:03:06.757Z Agios Cuts Over 100 R&D Roles While FDA Delays Sickle Cell Ruling Agios, layoffs, mitapivat, sickle cell disease, FDA https://pharmoniq.com/news/rhythm-shares-jump-on-reported-astrazeneca-bid PharmoniQ en 2026-11-07T14:05:16.601Z Rhythm Shares Jump 28% on Reported AstraZeneca Takeover Bid AstraZeneca, Rhythm Pharmaceuticals, M&A, Obesity, Rare disease https://pharmoniq.com/news/lonza-to-buy-5-us-plants-from-merck-kgaa PharmoniQ en 2026-11-07T07:58:45.931Z Lonza to Buy 5 US Plants From Merck KGaA, Adding About 1,100 Staff Lonza, Merck KGaA, CDMO, manufacturing, antibody-drug conjugates